| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY | /s/ Judit Ryvkin, Attorney-in-Fact | 12 Aug 2025 | 0001197350 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MIRM | Common Stock | Sale | -8,000 | -22% | 28,236 | 11 Aug 2025 | Direct | F1, F2 | ||
| transaction | MIRM | Common Stock | Options Exercise | $78,251 | +2,954 | +10% | $26.49 | 31,190 | 12 Aug 2025 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MIRM | Employee Stock Option (right to buy) | Options Exercise | $0 | -2,954 | -9.2% | $0.000000 | 29,046 | 12 Aug 2025 | Common Stock | 2,954 | $26.49 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | The weighted average sale price for the transaction reported was $65.50, and the range of prices were between $65.31 and $66.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| F2 | Includes 290 shares of Common Stock that were acquired by the Reporting Person on May 10, 2025 pursuant to the Issuer's Employee Stock Purchase Plan. |
| F3 | 1/4th of the shares vested one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. |